Search Results

PARP1-selective inhibitor Demonstrates Early Efficacy in Breast Cancers with DNA Repair Defects
Biotechnology

PARP1-selective inhibitor Demonstrates Early Efficacy in Breast Cancers with DNA Repair Defects

MBT Desk
2 min read
Saruparib is a new-generation oral inhibitor selectively targeting PARP1. The improved safety profile can allow for more combinations to bring benefits to patients in earlier disease stages.
ALS is a degenerative disease of the nervous system particularly affecting and harmful to motor neurons. (Representational image: Wikimedia Commons)
Medicine

Pharmacological Inhibitor Protects Nerve Cells in ALS Disease

MBT Desk
3 min read
New Drug Shows Promise in Treating ALS
Combination of inhibitors may suppress tumor growth and prevent relapse in patients with certain cancers, including head and neck squamous cell carcinoma and lung adenocarcinoma. (Representational Image: Unsplash)
Medicine

A Combination of Cancer Inhibitors Shows Success in Slowing Tumor Growth

MBT Desk
3 min read
Cancer Inhibitors (AXL and EGFR) combined hold promise in fighting certain head, neck, and lung cancers
Biomedicine relies upon the use of protein inhibitors based on the assumption that lowering disease-promoting protein levels or activity is generally beneficial when treating cancer.
Biotechnology

Rethinking the Protein Inhibitor Approach to Cancer Therapy

MBT Desk
4 min read
New cell manipulation method that controls metastasis activator protein BACH1 shows inhibiting it sometimes results in further cancer cell invasion; discovery highlighted in Nature Chemical Biology
Nearly 90% of late-stage lung cancer patient deaths are caused by the spread of tumors to other organs
Fitness and Wellness

Fibroblast Inhibitors Assist Anti-Cancer Drugs to Suppress Cancer Growth

MBT Desk
2 min read
Fibroblasts build and maintain the extracellular matrix, or physical scaffolding for cells, in the connective tissues within the body.
Patients with so called heart failure with improved ejection fraction (HFimpEF) remain at high risk for adverse outcomes. (Image : Unsplash)
Medicine

Patients With Heart Failure Benefit From SGLT2 Inhibitor

MBT Desk
2 min read
Study finds that patients with heart failure with improved ejection fraction benefit from the SGLT2 inhibitor dapagliflozin.
Read More
logo
Medbound
www.medboundtimes.com